bioAffinity Technologies (BIAF) Return on Sales (2022 - 2026)

bioAffinity Technologies has disclosed Return on Sales across 5 years of filings, most recently posting 0.03% for Q1 2026.

• In Q1 2026, Return on Sales fell 1.0% year-over-year to 0.03%; the TTM figure through Mar 2026 stood at 0.03% (down 2.0% YoY), while the FY2025 annual figure was 0.02%, down 1.0% from the prior year.
• Return on Sales slipped to 0.03% in Q1 2026, from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for BIAF reached as high as 0.01% in Q1 2024 and fell as low as 42.78% in Q3 2022.
• The 5-year median for Return on Sales is 0.03% (2025), against an average of 4.27%.
• The widest YoY moves for Return on Sales: up 4270 bps in 2023, down 21 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 7.14% in 2022, then surged by 100 bps to 0.01% in 2023, then dropped by 25 bps to 0.01% in 2024, then sank by 47 bps to 0.02% in 2025, then sank by 36 bps to 0.03% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.03%, 0.02%, and 0.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.